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Leishmaniasis and trypanosomiasis are two neglected and potentially lethal diseases that
affect mostly the poor and marginal populations of developing countries around the world
and consequently have an important impact on public health. Clinical manifestations such as
cutaneous, mucocutaneous, and visceral disorders are the most frequent forms of leishma-
niasis, a group of diseases caused by several Leishmania spp. American trypanosomiasis,
or Chagas disease, is caused by Trypanosoma cruzi, a parasite that causes progressive
damage to different organs, particularly the heart, esophagus, and lower intestine. African
trypanosomiasis, or sleeping sickness, is caused by Trypanosoma brucei and is character-
ized by first presenting as an acute form that affects blood clotting and then becoming
a chronic meningoencephalitis. The limited number, low efficacy, and side effects of con-
ventional anti-leishmania and anti-trypanosomal drugs and the resistance developed by
parasites are the major factors responsible for the growth in mortality rates. Recent
research focused on plants has shown an ingenious way to obtain a solid and potentially rich
source of drug candidates against various infectious diseases. Bioactive phytocompounds
present in the crude extracts and essential oils of medicinal plants are components of
an important strategy linked to the discovery of new medicines. These compounds have
proven to be a good source of therapeutic agents for the treatment of leishmaniasis and
trypanosomiasis. This work highlights some chemotherapeutic agents while emphasizing
the importance of plants as a source of new and powerful drugs against these widespread
diseases.
Keywords: leishmaniasis, Chagas disease, sleeping sickness,Trypanosoma spp., Leishmania spp., chemotherapy,
medicinal plants, phytotherapy
INTRODUCTION
Leishmaniasis and trypanosomiasis are neglected tropical diseases
caused by protozoans of the Trypanosomatid family, a diverse
group of flagellated parasites that show similar cellular structures
and undergo morphological alterations during their life cycles. The
human diseases caused by trypanosomatids such as leishmaniasis,
African trypanosomiasis (or sleeping sickness), and American try-
panosomiasis (or Chagas disease) are transmitted by insects that
affect 20 million people and cause 100,000 deaths per year, pri-
marily in the tropical and subtropical areas of the world. In these
regions, half of a billion people are at risk of infection (Stuart et al.,
2008).
According to the World Health Organization (WHO), an ideal
drug for the treatment of parasitic diseases should fulfill the fol-
lowing requirements: (i) parasitological cure in all the phases
of the disease; (ii) effective in single or few doses; (iii) low
cost for the patients; (iv) no collateral or teratogenic effects;
(v) no need for hospitalization; and (vi) no induction of resis-
tance. As described below, this ideal drug does not exist for
the treatment of these parasitoses, and it will take a long time
before such a drug is available. Additionally, because the vac-
cine approach has not produced satisfactory results in clinical
trials, chemotherapy based on drugs that are not highly effec-
tive and cause side effects is the only treatment available for these
maladies.
Considering the low number and efficacy of drugs available for
the treatment of these diseases as well as their side effects and the
resistance developed by parasites, the research in phytosciences,
mainly regarding the properties of bioactive phytocompounds in
the crude extracts and essential oils of medicinal plants, may lead
to the discovery of new medicines with appropriate efficiency that
are more accessible to the patients (Alviano and Alviano, 2009).
Overall this review aims to provide a better understanding of the
recent developments of the phytosciences to treat leishmaniasis
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and trypanosomiasis neglected tropical diseases in terms of drug
discovery and development in the world today.
LEISHMANIASIS, CHAGAS DISEASE, AND SLEEPING
SICKNESS
Leishmaniasis is a generic term for diverse clinical manifesta-
tions including cutaneous, mucocutaneous, and visceral disorders
caused by species of the genus Leishmania. All Leishmania species
display similar morphologies and present two main developmen-
tal stages throughout their life cycles. The extracellular replicative
forms, the promastigotes, are found in the gut of the insect vec-
tors, the phlebotomines sandfly. The amastigote is the obligatory
intracellular form observed in the mononuclear phagocytic sys-
tem cells of vertebrate hosts. During blood feeding, the infected
sandflies expel, together with saliva, a number of infective pro-
mastigotes found at the cardiac valve. Cutaneous leishmaniasis
(CL), mucocutaneous leishmaniasis (MCL), and visceral leishma-
niasis (VL) have a high impact in several countries of the world due
to their morbidity and mortality rates. Many Leishmania species
act as etiological agents of cutaneous and MCL; one of the most
well known agents of the diffuse cutaneous form is Leishmania
amazonensis and MLC forms is L. brasiliensis. On the other hand,
L. donovani and L. chagasi are the only etiological agents of VL.
The CL is characterized by lesions on the face, hands, and/or feet.
MCL involves the nasal, oral, and pharyngeal mucosa and causes
difficulty in eating as well as an increased risk of secondary infec-
tions that have a significant mortality rate (Murray et al., 2005;
Piscopo and Mallia, 2007; David and Craft, 2009). The VL is char-
acterized by fever, weakness, and fatigue are worsened by anemia,
which is caused by a persistent inflammatory state, hypersplenism,
and sometimes by bleeding. As the disease advances, splenomegaly
and hepatomegaly can increase, causing abdominal distension and
pain. These VL symptoms often persist for a long time before the
patient either seeks medical care or dies from secondary infections,
severe anemia, or organ failure (Chappuis et al., 2007; Piscopo and
Mallia, 2007).
The life cycle ofTrypanosoma cruzi, the etiological agent of Cha-
gas disease, involves blood sucking by triatomine bugs that serve
as insect vectors and a mammalian host where the parasite under-
goes an obligate intracellular amastigote replicative form and an
extracellular non-replicative trypomastigote form in the blood-
stream. The epimastigote replicative form and a non-replicative
infective metacyclic trypomastigote form are also observed in the
insect vector. This disease is mainly transmitted by insect vectors
feces, but transmission may also occur by blood transfusion, organ
transplant, congenital and oral routes, and laboratory accidents.
The prevalence and incidence of Chagas disease and the associated
mortality are constantly changing as a consequence of vector con-
trol programs, rural-urban human migration, and changes in the
socio-economic status of risk areas (Lewinsohn, 2003; Moncayo
and Ortiz Yanine, 2006).
Despite the fact that most people infected with the parasite
never appear to become symptomatic, Chagas disease presents
in two stages: the acute stage, which appears shortly after the
infection, and the chronic stage, which may last several years.
In the acute phase, fever, lymphadenopathies, hepatomegaly, and
splenomegaly may appear, as well as more severe problems, such as
acute myocarditis and meningoencephalitis, which may be fatal in
2–8% of the cases in the absence of specific treatment (Moncayo
and Ortiz Yanine, 2006; Develoux et al., 2009).
African trypanosomiasis or sleeping sickness occurs only in 36
countries in sub-Saharan Africa that contain vector insects of the
genus Glossina (tsetse flies). Sleeping sickness is a serious public
health problem in these countries because 55 million people are at
risk of infection and there are an estimated 30,000 new cases annu-
ally. If left untreated, the disease is almost always fatal. Its etiologic
agents are two subspecies of Trypanosoma brucei, T. b. gambiense
in West Africa, and T. b. rhodesiense in East Africa, and the last
is responsible for most severe form of the same disease. The try-
panosomes of the brucei group primarily infect connective tissues.
Hemolytic anemia occurs in the early stages of infection, followed
by lymph node, spleen, and liver hypertrophy and cardiovascular
and endocrine disorders. In the final phase of the infection, the par-
asites reach the nervous system and cause inflammatory reactions
that lead to the meningoencephalitis associated with the clinical
aspects of sleeping sickness (Gehrig and Efferth, 2008; Astelbauer
and Walochnik, 2011).
CURRENT CHEMOTHERAPY AGAINST LEISHMANIASIS,
CHAGAS DISEASE, AND SLEEPING SICKNESS AND IMPACT
OF PARASITE RESISTANCE
Chemotherapy is the main tool used to control parasitic infections.
The drugs available for these parasites control are often ineffective
and sometimes life-threatening, adverse side effects, and some of
these drugs require hospitalization (Croft et al., 2006; Ashutosh
and Goyal, 2007; Piscopo and Mallia, 2007).
The drugs available for leishmaniasis infections are the pen-
tavalent antimonial formulations of sodium stibogluconate (Pen-
tostan) and N -methyl glucantime (Glucantime), which target
the amastigotes of both CL and VL. Of the various proposed
mechanisms of action for these two drugs, we can mention the
production of ATP inhibition of the citric acid cycle and glycol-
ysis by converting the pentavalent antimony the active trivalent
antimony which is more active and more toxic, inhibition of oxi-
dation of fatty acids in amastigotes and induction of apoptosis
and inhibition of the enzyme DNA topoisomerase (Berman et al.,
1987; Frézard et al., 2009). Variations in the clinical responses to
these drugs have been a persistent problem in the treatment of
leishmaniasis over the past 50 years due to intrinsic differences
in species sensitivity and the development of resistance. When
these drugs are ineffective or cannot be prescribed, treatment
with amphotericin B, pentamidine, or paromomycin is indicated.
However, as none of these drugs are free of adverse effects, the
search for alternative therapeutic agents is essential. The combi-
nation of amphotericin B liposome is an alternative employed to
reduce adverse effects, increasing the efficiency of the drug. As flu-
conazole and ketoconazole, azoles which initially were designed
for the treatment of fungal infections, have been used for treat-
ing CL. Miltefosine has been recently approved as the first oral
drug for VL. It yields cure rates of approximately 98% and is
used to treat cases of resistance to antimoniates; however, it has
been shown to induce parasite resistance in vitro (Croft et al.,
2006; Santos et al., 2008; Goto and Lindoso, 2010; Tiuman et al.,
2011).
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Nifurtimox (Nif; Bayer 2502) and benznidazole (Bz; RO 7-
1051) have been used for the treatment of Chagas disease since
the end of 1960. The mechanism of action of Nif is based on a
partial deficiency in the ability of T. cruzi to detoxify free radi-
cals. Nif leads to the formation of nitro anion radicals that in turn
produce highly toxic reduced oxygen metabolites. However, Nif is
no longer commercially available. Instead of producing oxidative
damage, the Bz mechanism of action might involve covalent mod-
ifications of parasite proteins, lipids, and DNA by nitro reduction
intermediates (Coura and de Castro, 2002). The likelihood of cur-
ing Chagas disease with Nif and Bz varies according to the phase
of the disease, the period of treatment, the dosage, and the age
of the patient. Usually, satisfactory results are achieved when the
patients are treated in the acute phase, in recent chronic infec-
tion, in congenital infection, and after laboratory accidents. The
major limitation of these compounds is the low efficacy in the
treatment of patients in the chronic phase of the disease (Coura
and de Castro, 2002).
Treating infections with Nif may lead to collateral effects such
as psychic alterations, anorexia, excitability, sleepiness, and diges-
tive manifestations (nausea, vomiting, and diarrhea). Doses of Bz
for Chagas disease treatment may cause hypersensitivity leading to
dermatitis with cutaneous eruptions and generate neuropatholo-
gies such as paresthesia and polyneuritis of the peripheral nerves.
However, the most serious reaction to Bz is the depression of bone
marrow that leads to thrombocytopenic purpura and agranulocy-
tosis. Due to these characteristic side effects, Nif and Bz should not
be used by elderly or pregnant patients or by patients presenting
any severe disease associated with Chagas disease, such as cardiac,
respiratory, renal, or hepatic insufficiency, systemic infection, and
neoplasia (Coura and de Castro, 2002).
The use of nanotechnology as liposomes, antibody conjugates,
and nanoparticles as drug carriers can overcome anatomical barri-
ers and take the drug directly to the site of action, reaching the tar-
get microorganisms, and reducing their side effects. Alternatively,
amphotericin B can be used as a second line treatment in Cha-
gas disease using nano-drug delivery systems (Yardely and Croft,
1999; Romero and Morilla, 2010). The E1224 azole compound,
a prodrug transformed into ravuconazole in vivo, discovered and
developed by Esai Pharmaceuticals had preclinical and clinical
phase I studies completed. This promising compound for the treat-
ment of Chagas disease, has been tested in phase II clinical studies
in adult patients in Bolivia [Drugs for Neglected Diseases Inicia-
tive (DNDi), 2012]. Furthermore, the ravuconazol was evaluated
extensively in animal models (Diniz et al., 2010).
The treatment for sleeping sickness depends on the stage of
the disease. The drugs used in the first stage of the disease have
a low toxicity and are easy to administer. Therefore, early iden-
tification results in an increased potential for curing the disease.
Treatment success in the second stage of disease depends on a
drug that can cross the blood-brain barrier to reach the parasite.
Such drugs are toxic and complicated to administer. There are four
drugs typically used for the treatment of sleeping sickness. Early
infections are treated with pentamidine and suramin. Pentami-
dine is used for the treatment of the first stage of T. b. gambiense
sleeping sickness. It has few undesirable effects and is generally
well tolerated by patients. Suramin is used for the treatment of
the first stage of sleeping sickness by T. b. rhodesiense but can
cause allergic reactions and some undesirable effects in the uri-
nary tract. In their final stages, both forms of infections are treated
with melarsoprol, a drug derived from arsenic. This drug has many
side effects, the most dramatic of which is reactive encephalopathy,
which can be fatal, and kills up to 5% of patients. It is supposed
that the mechanism of action is the interaction of the drug with a
transporter specific for adenosine reducing the absorption of these
nucleoside by the parasite and by the arsenic binding to glycerol
3-phosphate dehydrogenase, resulting in inhibition of glycolysis,
and low levels of ATP (Denise and Barret, 2001). Another option
is eflornithine, which is less toxic but only effective against T. b.
gambiense infections. A combination treatment with nifurtimox
and eflornithine was recently (2009) introduced, but is not effec-
tive for T. b. rhodesiense (Wilkinson and Kelly, 2009; Astelbauer
and Walochnik, 2011; Jacobs et al., 2011).
One major drawback to the treatment of leishmaniasis, Cha-
gas disease, and sleeping sickness is the emergence of resistance
to current chemotherapeutics. Due to their high toxicity, drugs
usually used for the treatment of these diseases have to be admin-
istered in low doses, allowing drug resistance to develop. Because
there are few drugs available for the treatment of these para-
sitoses, resistance has a considerable impact on the control of these
maladies.
The primary mechanism generally observed in parasite resis-
tance is a decrease in the drug concentration within the parasite
cell. The drug level may be lowered by a variety of mechanisms,
including decreased uptake, increased efflux, and inhibition of
drug activation and inactivation of active drug by the metabolism.
In recent years, a large-scale increase in clinical resistance of Leish-
mania to pentavalent antimonials has been reported. The mech-
anisms of resistance of Leishmania spp. and T. cruzi against the
chemotherapeutics developed in the field are not elucidated, and
most of our knowledge stems from work on laboratory mutants
(Nogueira et al., 2006; Ashutosh and Goyal, 2007).
The resistance mechanisms in T. b. rhodesiense and T. b. gambi-
ense, recently reviewed by Gehrig and Efferth (2008), are frequently
mediated by a reduced net drug uptake. Another drug resistance
mechanism for melarsoprol is the overexpression of efflux pumps
(Mäser et al., 2003).
A study using RNA interference in T. brucei showed the loss of
function of a nitroreductase and an amino acid transporter nec-
essary for activation of the prodrug nifurtimox and acquiring of
eflornithine, respectively, showing the mechanisms of resistance
to these two drugs (Baker et al., 2011).
PLANTS AS PROMISING SOURCES OF ANTI-LEISHMANIAL
AND ANTI-TRYPANOSOMAL COMPOUNDS
Considering the lack of vaccines, the toxicity of the chemother-
apies, the side effects of the treatment, and the resistance of the
parasites to the drugs, there is an evident need to discover drugs
that can be used as therapeutics for leishmaniasis, sleeping sick-
ness, and Chagas disease. In recent years, many pharmacologically
active and microbicidal compounds derived from plants have been
discovered (Cowan, 1999; Alviano and Alviano, 2009; Izumi et al.,
2011), indicating that phytoscience is important in the search of
novel compounds with a potential to control these diseases.
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Table 1 | Plants and identified antiprotozoal bioactive phytocompounds.
Scientific name Major components Effects Parasites Reference
Drymis brasiliensis Polygodial Cell proliferation (promastigotes), Cell
viability (trypomastigotes),
mitochondrial changes, nuclear
changes, plasma membrane damages
(promastigotes)
L. amazonensis,
L. braziliensis,
L. chagasi, L. major,
Trypanosoma cruzi
Corrêa et al. (2011)
Baccharis retusa Sakuranetin Cell proliferation (promastigotes), Cell
viability (trypomastigotes), activity in
intracellular amastigotes
L. amazonensis, L.
braziliensis, L. chagasi,
L. major,T. cruzi
Grecco et al. (2012)
Ocimum gratissimum Eugenol Cell lysis e proliferation
(promastigotes), mitochondrial
changes, stimulation of NO production
in macrophages
L. amazonensis
Trypanosoma brucei
rhodesiense
Ueda-Nakamura et al.
(2006), Abiodun et al. (2012)
Croton cajucara Linalool, acetyl
aleuritolic acid
Mitochondrial changes
(promastigotes), activity in intracellular
amastigotes. Cell viability
(trypomastigotes), activity in
intracellular amastigotes,
mitochondrial, and kinetoplast changes
(epimastigotes)
L. amazonensis, T. cruzi Rosa et al. (2003), Campos
et al. (2010)
Piper claussenianum Trans-nerolidol Cell proliferation, activity in intracellular
amastigotes, increased NO production
in infection macrophages, decreased
arginase activity of the parasite
L. amazonensis Marques et al. (2010, 2011)
Lippia alba Geranial, neral, geraniol,
and
trans-β-caryophyllene
Cell proliferation (epimastigotes) and
intracellular amastigotes activity
T. cruzi Escobar et al. (2010)
Lippia origanoides Oxygenated
monoterpenes
Cell proliferation (promastigotes) L. chagasi Escobar et al. (2010)
Moringa stenopetala Benzyl-isothiocyanate Cell proliferation (bloodstream forms) Trypanosoma brucei
brucei
Nibret and Wink (2010)
Hagen abyssinica Ledol Cell proliferation (bloodstream forms) T. b. brucei Nibret and Wink (2010)
Leonotis ocymifolia Caryophyllene oxide Cell proliferation (bloodstream forms) T. b. brucei Nibret and Wink (2010)
Cupania cinerea Cupacinoside, taraxerol Cell proliferation (bloodstream forms) T. b. rhodesiense Gachet et al. (2011)
Kola acuminata Proanthocyanidin Cell proliferation (bloodstream forms
and procyclic forms), cell lysis and
changes in plasma membrane
T. brucei (clone221a) Kubata et al. (2005)
Salvia hydrangea Salvadione, perovskone Cell proliferation (bloodstream forms) T. b. rhodesiense Farimani et al. (2011)
Carlina acaulis Carlina oxide
(polyacetylene)
Cell proliferation (bloodstream forms) T. b. brucei Herrmann et al. (2011)
Syzygium aromaticum Eugenol Cell proliferation and viability
(epimastigotes and bloodstreams
trypomastigotes) and loss of nuclear
content, and masses of condensed
chromatin (trypomastigotes)
T. cruzi Santoro et al. (2007)
Ocimum basilicum Linalool Cell proliferation and viability
(epimastigotes and bloodstreams
trypomastigotes), cytoplasmic
extraction and nuclear alteration
(epimastigotes)
T. cruzi Santoro et al. (2007)
Achillea millefolium Chamazulene Cell proliferation and viability
(epimastigotes and bloodstream
trypomastigotes)
T. cruzi Santoro et al. (2007)
(Continued)
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Table 1 | Continued
Scientific name Major components Effects Parasites Reference
Zanthoxylum chiloperone Chantin-6-one Cell lysis (bloodstream
trypomastigotes), anti amastigotes
activity and in vivo activity in infected
mice
T. cruzi Ferreira et al. (2011)
Centaurea salmantica Cynaropicrin Cell proliferation (bloodstream
trypomastigotes), In vivo activity
(reduction of parasitemia)
T. b. rhodesiense, T. b.
gambiense
Zimmermman et al. (2012)
Lippia sidoides Thymol Cell proliferation, accumulation of lipid
droplets, wrinkled, or ruptured
membranes and the loss of cytoplasm
(promastigotes)
L. amazonensis Medeiros et al. (2011)
Cymbopogon citratus Citral Cell proliferation, ultrastructural
alterations like mitochondrial and
kinetoplast swelling and disruption of
nuclear membrane, loss of
mitochondrial membrane potential and
other alterations
L. infantum, L. major,
L. tropica
Machado et al. (2012)
Ambrosia scabra Psilostachyin C Cell proliferation (epimastigotes and
promastigotes), ultrastructural
changes, anti amastigotes activity,
In vivo activity (reduction of
parasitemia)
T. cruzi, L. amazonensis, L.
mexicana
Sülsen et al. (2011)
Chamomilla recutita (−) α-bisabolol Cell proliferation (promastigotes) L. infantum Morales-Yuste et al. (2010)
Xanthium strumarium Xanthatin Cell proliferation (bloodstream forms),
mitochondrial membrane potential
reduction, trypanothione reductase
inhibition
T. b. brucei Nibret et al. (2011)
Saussurea costus Sesquiterpene lactones Cell proliferation (bloodstream forms) T. b. rhodesiense Julianti et al. (2011)
Piper aduncum 2′,6′-dihydroxy-4′-
methoxychalcone
Cell proliferation (promastigotes),
mitochondrial damage, anti-intracellular
amastigote activity
L. amazonensis Torres-Santos et al. (1999)
Piper rusbyi Kavapyrone, Flavokavain Cell proliferation (promastigotes)
In vivo activity (lesion size reduction)
L. amazonensis,
L. braziliensis, L. donovani
Flores et al. (2007)
Piper auritum Safrole Cell proliferation (promastigotes),
anti-intracellular amastigote activity
L. major, L. mexicana,
L. braziliensis, L. donovani
Monzote et al. (2010)
Piper regnellii Eupomatenoid-5 Cell proliferation (promastigotes and
axenic amastigotes), anti-intracellular
amastigotes Ultrastructural alteration
and lipoperoxidation in the cell
membrane (epimastigotes and
bloodstream forms)
L. amazonensis
Trypanosoma cruzi
Vendrametto et al. (2010),
Pelizzaro-Rocha et al. (2011)
Aframomum sceptrum Sceptrumlabdalactone
B
Cell proliferation (promastigotes and
bloodstream forms)
L. donovani T. b. brucei Cheikh-Ali et al. (2011)
In fact, promising results have been obtained by our group
and others in the search of plant-derived crude extracts,
essential oils, and compounds with activity against path-
ogenic microorganisms, including Leishmania spp., T. cruzi
(Alviano and Alviano, 2009; Izumi et al., 2011), and T. brucei
(Gehrig and Efferth, 2008). Useful antiprotozoal phytocom-
pounds can be divided into several categories summarized in
Table 1.
ANTI-LEISHMANIAL COMPOUNDS
Essential oils are known to possess a wide variety of hydropho-
bic compounds with antimicrobial potential. The ability to dif-
fuse across cell membranes certainly gives to those molecules
some advantage in targeting cellular components, being a valuable
research option for the search of bioactive compounds (Bakkali
et al., 2008). The Ocimum gratissimum essential oil and eugenol,
its major component, was tested on the growth, viability, and
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FIGURE 1 | Effects of linalool-rich essential oil (15.0 ng/ml) extracted
from C. cajucara on the promastigote stage of L. amazonensis, as
observed by transmission electron microscopy. (A) Control parasites;
(B–E) parasites treated for 5 (B), 10 (C), 15 (D), and 30 (E) min, showing
promastigotes with different degrees of damage. Note the disruption of
the flagellar membranes [arrowheads in (B,C)], the mitochondrial
swelling (C,D), and the gross alterations in the organization of the
nuclear and kinetoplast chromatins (C,D). In the presence of the
essential oil, the parasites were completely destroyed after 30 min of
treatment (E). N, nucleus; K, kinetoplast, F, flagellum. Bars, 1µm. Image
reproduced with permission from © Rosa et al. (2003) American Society
for Microbiology.
ultrastructural alterations of the amastigote and promastigote
forms of L. amazonensis, as well as on the interaction of these flagel-
lates with mouse peritoneal macrophages, concomitant with nitric
oxide production stimulation by the infected macrophages. Sig-
nificant mitochondrial alterations occurred at the ultrastructural
level of the parasite, such as remarkable swelling, disorganiza-
tion of the inner membrane, and an increase in the number of
cristae after treatment of parasites with O. gratissimum essen-
tial oil. However, mouse macrophages were unaffected under the
same conditions. In addition, nitric oxide production was dra-
matically stimulated when mouse peritoneal macrophages were
treated with 150µg/ml essential oil, both before and after infection
with L. amazonensis. Concomitantly, the association indexes were
drastically lower in the latter conditions, compared to the control
system (Ueda-Nakamura et al., 2006).
The linalool-rich essential oil extracted from the leaves of Cro-
ton cajucara, has effects onL. amazonensis parasites, on the interac-
tion of these flagellates with mouse peritoneal macrophages and on
nitric oxide production by the infected macrophages. The median
lethal doses and absolute lethal doses of the essential oil and
linalool-rich essential oil from C. cajucara for promastigotes and
amastigotes were very low. Mitochondrial swelling and alterations
in the organization of the nuclear and kinetoplast chromatins were
observed by electron microscopy when L. amazonensis parasites
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FIGURE 2 | Structure of cupacinoside and taraxerol. Reprinted (adapted) with permission from © Gachet et al. (2011) American Chemical Society.
FIGURE 3 | Effects of Kola acuminate proanthocyanidin (50µg) on
bloodstream form trypanosomes observed by scanning and
transmission electron microscopy. (A) Control parasites showing the
normal cell morphology and membrane integrity. (B,C) Parasites treated for
6 h showing morphological changes and the rounding up of the cells. (D,E)
Cells showing disintegrated cell membranes and loss of cytoplasmic contents
caused by the effect of the drug. (F) TEM of a trypanosome cell confirming
the necrotic process of cell membrane disintegration and loss of cytoplasmic
contents that led to cell death. Scale bar: 1µm. Image reproduced with
permission from © Kubata et al. (2005) Elsevier.
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FIGURE 4 | Structure of salvadione and perovskone. Reprinted (adapted) with permission from © Farimani et al. (2011) American Chemical Society.
were treated with the essential oil from C. cajucara (Figure 1).
The viability of mouse macrophages was unaffected by the same
concentrations. When the macrophages were pre-treated with C.
cajucara essential oil, as well as when the macrophages were pre-
infected with the parasites and then treated with the essential oil,
the association indexes were 50% lower than those for the control
system. In addition, the macrophages pre-treated with C. caju-
cara essential oil produced twice the amount of nitric oxide as the
untreated macrophages (Rosa et al., 2003).
Piper species have been reported to have activity against Leish-
mania parasites (Torres-Santos et al., 1999; Flores et al., 2007;
Sarkar et al., 2008). Our group recently showed that the leaf essen-
tial oil from Piper claussenianum was able to inhibit the growth
of L. amazonensis promastigotes with an IC50 of 0.0038% (Mar-
ques et al., 2010). Trans-nerolidol is a major component of this
essential oil. We also examined the effect of the essential oil on
the interaction between parasites and host cells and its activity
against intracellular amastigotes. The IC50 concentration used
against promastigotes yielded a 31% reduction in the percent-
age of infected macrophages and led to a 17% increase in the
production of NO by macrophages. The activity of the enzyme
arginase may be able to modulate nitric oxide production by
macrophages by inhibiting nitric oxide synthase (iNOS). Pro-
mastigotes were grown in the presence of the IC50 of the essential
oil and showed a 62% reduction in arginase activity. (Marques
et al., 2011). Monzote et al. (2010) described the anti-leishmanial
activity of the essential oil from Piper auritum. In that study, essen-
tial oil inhibited the growth of promastigotes in all species of
Leishmania used, with IC50 values between 12.8 and 63.3µg/mL.
In addition, piper-oil inhibited the growth of intracellular amastig-
otes of L. donovani at non-toxic concentrations (Monzote et al.,
2010).
ANTI-TRYPANOSOMIAL COMPOUNDS
One new diterpene glycoside, cupacinoside, and one known com-
pound, taraxerol (Figure 2) from n-hexane, and dichloromethane
extracts from the bark of Cupania cinerea (Sapindaceae) have
shown significant in vitro activity against one of the etiologic
agents of sleeping sickness. Cupacinoside and taraxerol showed
IC50 values <10µM against T. b. rhodesiense, with taraxerol
exhibiting only low cytotoxicity against rat skeletal myoblast cell
line (L-6 cells; Gachet et al., 2011).
A proanthocyanidin isolated from Kola acuminate seeds was
able to inhibit the proliferation and cause the lysis of Try-
panosoma brucei bloodstream forms in vitro. The in vivo effect
was trypanostatic and prolonged the survival of infected ani-
mals that were treated with this substance. Additionally, it was
not toxic to the human epidermoid carcinoma cells (KB 3-1), but
it caused ultrastructural changes in parasites, such as rupture of
the plasma membrane and vesicles and the formation of multi-
vesicular bodies in lysosome-like organelles, when the parasites
were treated for 6 h with the compound (Figure 3; Kubata et al.,
2005).
Salvadione and perovskone (Figure 4), two new triterpenoids
with rare carbon skeletons isolated from aerial parts and flowers
of Salvia hydrangea were used in the treatment of leishmania-
sis in Iran. These compounds were tested in vitro against T. b.
rhodesiense and exhibited moderated potency with IC50 values
4.33 and 15.92µM, respectively and good selectivity index for L-6
cells (Farimani et al., 2011).
A study using essential oils of cloves (Syzygium aromaticum),
basil (Ocimum basilicum), and a yarrow (Achillea millefolium)
and the main constituents, eugenol and linalool showed activ-
ity on T. cruzi bloodstream trypomastigotes and epimastigotes
forms. The essential oils inhibited epimastigotes proliferation,
caused trypomastigotes lysis and ultrastructural changes in both
forms, mainly in the nucleus. In epimastigotes forms was observed
shrinkage of the nuclear material with separation of the nuclear
membrane and in trypomastigotes forms loss nuclear material
and masses of condensed chromatin appeared (Santoro et al.,
2007).
Acetyl aleuritolic acid, a terpene isolated from the methano-
lic extract of stem bark of C. cajucara showed significant try-
panocidal effect in trypomastigotes of a strain isolated from wild
reservoirs (GLT291), genotype TCI as clone Dm28c. was also
effective against intracellular amastigotes and did not show a
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significant effect on proliferative epimastigotes. This compound
was also able to inhibit the activity of trypanothione reductase,
an important enzyme in the regulation of redox balance and
defense against oxidative stress in this parasite (Campos et al.,
2010). Xanthatin, a sesquiterpene lactone, was described by Nibret
et al. (2011) as strong trypanocidal agent with an IC50 value of
2.63µg/mL. According to the authors, it seems that the biological
activity of the compound is a result of its effect in inducement
of apoptosis in trypanosomes as evidenced by a reduction in
mitochondrial membrane potential. Furthermore, xanthatin was
able to inhibit the two key enzymes involved in the inflammatory
process, cyclooxygenase and 5-lipoxygenase, which can be very
interesting in diseases that cause this kind of response (Nibret
et al., 2011).
CONCLUSION
At a time when there is an urgent need for the efficient treatment
of leishmaniasis, Chagas disease, and sleeping sickness, this review
shows that plant-derived extracts and compounds exhibit signif-
icant antiprotozoal activities in vitro and emphasizes the impor-
tance of phytoscience in the search for novel anti-leishmanial and
anti-trypanosomal therapeutic agents.
ACKNOWLEDGMENTS
This work was supported by Conselho Nacional de Desenvolvi-
mento Científico e Tecnológico (CNPq), Coordenação de Aper-
feiçoamento de Pessoal de Nível Superior (CAPES), and Fundação
Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de
Janeiro (FAPERJ).
REFERENCES
Abiodun, O. O., Gbotosho, G. O.,
Ajaiyeoba, E. O., Brun, R., and
Oduola, A. M. (2012). Antitry-
panosomal activity of some medici-
nal plants from Nigerian ethnomed-
icine. Parasitol. Res. 110, 521–526.
Alviano, D. S., and Alviano, C. S.
(2009). Plant extracts: search for new
alternatives to treat microbial dis-
eases. Curr. Pharm. Biotechnol. 10,
106–121.
Ashutosh, S. S., and Goyal, N. (2007).
Molecular mechanisms of antimony
resistance in Leishmania. J. Med.
Microbiol. 56, 143–153.
Astelbauer, F., and Walochnik, J. (2011).
Antiprotozoal compounds: state of
the art and new developments. Int. J.
Antimicrob. Agents 38, 118–124.
Baker, N., Alsford, S., and Horn,
D. (2011). Genome-wide RNAi
screens in African trypanosomes
identify the nifurtimox activator
NTR and eflornithine transporter
AAT6. Mol. Biochem. Parasitol. 176,
55–57.
Bakkali, F., Averbeck, S., Averbeck, D.,
and Idaomar, M. (2008). Biological
effects of essential oils – a review.
Food Chem. Toxicol. 46, 446–475.
Berman, J. D., Gallalle, J. V., and Best,
J. M. (1987). Sodium stibogluconate
(Pentostan) inhibition of glucose
catabolism via the glycolythic path-
way, and fatty acid ß-oxidation in
Leishmania mexicana amastigotes.
Biochem. Pharmacol. 36, 197–201.
Campos, M. C. O., Salomão, K., Castro-
Pinto, D. B., Leon, L. L., Barbosa,
H. S., Maciel, M. A. M., and Castro,
S. L. (2010). Croton cajucara crude
extract and isolated terpenes: activ-
ity on Trypanosoma cruzi. Parasitol.
Res. 107, 1193–1204.
Chappuis, F., Sundar, S., Hailu, A.,
Ghalib, H., Rijal, S., Peeling, R.
W., Alvar, J., and Boelaert, M.
(2007). Visceral leishmaniasis what
are the needs for diagnosis, treat-
ment and control. Nat. Rev. Micro-
biol. 5, 506–516.
Cheikh-Ali, Z., Okpekon, T., Roblot, F.,
Bories, C., Cardao, M., Jullian, J. C.,
Poupon, E., and Champy, P. (2011).
Labdane diterpenoids from Aframo-
mum sceptrum: NMR study and
antiparasitic activities. Phytochem.
Lett. 4, 240–244.
Corrêa, D. S., Tempone, A. G.,
Reimão, J. Q., Taniwaki, N. N.,
Romoff, P., Fávero, O. A., Sar-
torelli, P., Mecchi, M. C., and Lago,
J. H. G. (2011). Anti-leishmanial
and anti-trypanosomal potential
of polygodial isolated from stem
barks of Drymis brasiliensis Miers
(Winteraceae). Parasitol. Res. 109,
231–236.
Coura, J. R., and de Castro, S. L. (2002).
A critical review on Chagas disease
chemotherapy. Mem. Inst. Oswaldo
Cruz 97, 3–24.
Cowan, M. M. (1999). Plant products
as antimicrobial agents. Clin. Micro-
biol. Rev. 12, 564–582.
Croft, S. L., Sundar, S., and Fairlamb, A.
H. (2006). Drug resistance in leish-
maniasis. Clin. Microbiol. Rev. 19,
111–126.
David, C. V., and Craft, N. (2009). Cuta-
neous and mucocutaneous leishma-
niasis. Dermatol. Ther. 22, 491–502.
Denise, H., and Barret, M. (2001).
Uptake and mode of action of
drugs used against sleeping sickness.
Biochem. Pharmacol. 61, 1–5.
Develoux, M., Lescure, F. X., Le Loup,
G., and Pialoux, G. (2009). Mise au
point: Maladie de Chagas. Rev. Med.
Interne 30, 686–695.
Diniz, L. F., Caldas, I. S., Guedes, P. M.
N., Crepalde, G., Lana, M., Carneiro,
C. M., Talvani, A., Urbina, J. A., and
Bahia, M. T. (2010). Effects of ravu-
conazole treatment on parasite load
and immune response I dogs experi-
mentally infected with Trypanosoma
cruzi. Antimicrob. Agents Chemother.
54, 2979–2986.
Drugs for Neglected Diseases Inicia-
tive (DNDi). (2012). Available at:
http://www.dndi.org/portfolio/azoles-
e1224-and-biomarker.html
[accessed March 13, 2012]
Escobar, P., Leal, S. M., Herrera, L. V.,
Martinez, J. R., and Stashenko, E.
(2010). Chemical composition and
antiprotozoal activities of Colom-
bian Lippia spp essential oils and
their major components. Mem. Inst.
Oswaldo Cruz 105, 184–190.
Farimani, M. M., Bahadori, M. D.,
Taheri, S., Ebrahimi, S. N., Zim-
mermann, S., Brun, R., Amin,
G., and Hamburger, M. (2011).
Triterpenoids with rare carbon
skeleton from Salvia hydrangea:
antiprotozoal activity and absolute
configurations. J. Nat. Prod. 74,
2200–2205.
Ferreira, M. E., Cebrián-Torrejón, G.,
Corrales, A. S., Bilbao, N. V.,
Rolón, M., Gomez, C. V., Leblanc,
K., Yaluf, G., Schinini, T. S.,
Serna, E., Arias, A. R., Poupon,
E., and Fournet, A. (2011). Zan-
thoxylum chiloperone leaves extract:
first sustainable Chagas disease
treatment. J. Ethnopharmacol. 133,
986–993.
Flores, N., Cabrera, G., Jiménez, I. A.,
Pinero, J., Jiménez, A., Bourdy, G.,
Cortes-Selva, F., and Bazzocchi, I. L.
(2007). Leishmanicidal constituents
from the leaves of Piper rusbyi.
Planta Med. 73, 206–211.
Frézard, F., Demicheli, C., and Ribeiro,
R. R. (2009). Pentavalent antimoni-
als: new perspectives for old drugs.
Molecules 14, 2317–2336.
Gachet, M. S., Kuner, T. O., Kaiser, M.,
Brun, R., Zehl, M., Keller,W., Muñoz,
R. A., Bauer, R., and Schuehly,
W. (2011). Antiparasitic compounds
from Cupania cinerea with activities
against Plasmodium falciparum and
Trypanosoma brucei rhodesiense. J.
Nat. Prod. 74, 559–566.
Gehrig, S., and Efferth, T. (2008).
Development of drug resistance
in Trypanosoma brucei rhodesiense
and Trypanosoma brucei gambiense.
Treatment of human African try-
panosomiasis with natural prod-
ucts (Review). Int. J. Mol. Med. 22,
411–419.
Goto, H., and Lindoso, J. A. L. (2010).
Current diagnosis and treatment
of cutaneous and mucocutaneous
leishmaniasis. Expert Rev. Anti Infec.
Ther. 8, 419–433.
Grecco, S. S., Reimaõ, J. Q., Tempone,
A. G., Sartore, A. G., Sartorelli, P.,
Cunha, R. L. O. R., Romoff, P., Fer-
reira, M. J. P., Fávero, O. A., and Lago,
J. H. G. (2012). In vitro antileishma-
nial and antitrypanosomal activity
of flavanones from Baccharis retusa
DC. (Asteraceae).Exp. Parasitol. 130,
141–145.
Herrmann, F., Hamoud, R., Sporer, F.,
Tahrani, A., and Wink, M. (2011).
Carlina – a natural polyacety-
lene from Carlina acaulis (Aster-
aceae) with potent antrypanosomial
and antimicrobial properties. Planta
Med. 77, 1905–1911.
Izumi, E., Ueda-Nakamura, T., Dias
Filho, B. P., Veiga Junior, V. F.,
and Nakamura, C. V. (2011). Nat-
ural products and Chagas’ dis-
ease: a review of plant compounds
studies for activity against Try-
panosoma cruzi. Nat. Prod. Rep. 28,
809–823.
Jacobs, R. T., Nare, B., and Phillips, M.
A. (2011). State of the Art in African
Trypanosome drug discovery. Curr.
Top. Med. Chem. 11, 1225–1274.
Julianti, T., Hata, Y., Zimmermam,
S., Kaiser, M., Hamburger, M.,
and Adams, M. (2011). Antitry-
panosomal sesquiterpene lactones
fromSaussurea costus.Fitoterapia 82,
955–959.
www.frontiersin.org August 2012 | Volume 3 | Article 283 | 9
Alviano et al. Therapy against trypanosomatid parasites
Kubata, B. K., Nagamune, K.,
Murakami, N., Merkel, P., Kabu-
tutu, Z., Martin, S. K., Kalulu,
T. M., Mustakuk, H., Yoshida,
M., Ohnishi-Kameyama, M.,
Kinoshita, T., Duszenko, M., and
Urade, Y. (2005). Kola acuminata
proanthocyanidins: a class of anti-
trypanosomal compounds effective
against Trypanosoma brucei. Int. J.
Parasitol. 35, 91–103.
Lewinsohn, R. (2003). Prophet in his
own country: Carlos Chagas and the
Nobel Prize. Perspect. Biol. Med. 46,
532–549.
Machado, M., Pires, P., Diniz, A. M.,
Santos-Rosa, M., Alves, V., Salgueiro,
L., Cavaleiro, C., and Souza, M.
C. (2012). Monoterpenic aldehydes
as potential anti-Leishmania agents:
activity of Cymbopogon citratus and
citral on L. infantum, L. tropica
and L. major. Exp. Parasitol. 130,
223–231.
Marques, A. M., Barreto, A. L. S.,
Batista, E. M., Curvelo, J. A. R.,
Veloso, L. S. M., Moreira, D. L.,
Guimarães, E. F., Soares, R. M. A.,
and Kaplan, M. A. C. (2010). Chem-
istry and biological activity of essen-
tial oils from Piper claussenianum
(Piperaceae). Nat. Prod. Commun. 5,
1837–1840.
Marques, A. M., Barreto, A. L. S.,
Curvelo, J. A. R., Romanos, M. T.
V., Soares, R. M. A., and Kaplan,
M. A. C. (2011). Antileishmanial
activity of nerolidol-rich essential oil
from Piper claussenianum. Braz. J.
Pharmacognosy 21, 908–914.
Mäser, P., Lüscher, A., and Kamisnky, R.
(2003). Drug transporter and drug
resistance in African trypanosomes.
Drug Resist. Updat. 6, 281–290.
Medeiros, M. G. F., Silva, A. C., Citó, A.
M. G. L., Borges, A. R., Lima, S. G.,
Lopes, J. A. D., and Figueiredo, R. C.
B. Q. (2011). In vitro antileishmanial
activity and cytotoxicity of essen-
tial oil from Lippia sidoides Cham.
Parasitol. Int. 60, 237–241.
Moncayo, A., and Ortiz Yanine, M. I.
(2006). An update on Chagas dis-
ease (human American trypanoso-
miasis). Ann. Trop. Med. Parasitol.
100, 663–677.
Monzote, L., García, M., Montalvo,
A. M., Scull, R., and Miranda, M.
(2010). Chemistry, cytotoxicity and
antileishmanial activity of the essen-
tial oil from Piper auritum. Mem.
Inst. Oswaldo Cruz 105, 168–173.
Morales-Yuste, M., Morillas-Marquez,
F., Martín-Sanchéz, J., Valero-López,
A., and Navarro-Moll, M. C. (2010).
Activity of (-)α-bisabolol against
Leishmania infantum promastigotes.
Phytomedicine 17, 279–281.
Murray, H. W., Berman, J. D., Davies,
C. R., and Saraiva, N. G. (2005).
Advances in leishmaniasis. Lancet
366, 1561–1577.
Nibret, E., and Wink, M. (2010). Try-
panocidal and antileukaemic effects
of the essential oils of Hage-
nia abyssinica, Leonotis ocymifolia,
Moringa stenopetala and their main
individual constituents. Phytomedi-
cine 17, 911–920.
Nibret, E., Youns, M., Krauth-Siegel, R.
L., and Wink, M. (2011). Biologi-
cal activities of Xanthatin from Xan-
thium strumarium leaves. Phytother.
Res. 25, 1883–1890.
Nogueira, F. B., Krieger, M. A., Nirdé,
P., Goldenberg, S., Romanha, A. J.,
and Murta, S. M. (2006). Increased
expression of iron-containing super-
oxide dismutase-A (TcFeSOD-A)
enzyme in Trypanosoma cruzi pop-
ulation with in vitro-induced resis-
tance to benznidazole. Acta Trop.
100, 119–132.
Pelizzaro-Rocha, K. J., Veiga-Santos,
P., Lazarin-Bidóia, D., Ueda-
Nakamura, T., Dias Filho, B. P.,
Ximenes, V. F., Silva, S. O., and
Nakamura, C. V. (2011). Trypanoci-
dal action of eupomatenoid-5 is
related to mitochondrion dys-
function and oxidative damage in
Trypanosoma cruzi. Microbes Infect.
3, 1018–1024.
Piscopo, T. V., and Mallia, A. C. (2007).
Leishmaniasis. Postgrad. Med. J. 83,
649–657.
Romero, E. L., and Morilla, M. J. (2010).
Nanotechnology approaches against
Chagas disease.Adv. Drug Deliv. Rev.
62, 576–588.
Rosa, M. S., Mendonça-Filho, R. R.,
Bizzo, H. R., Rodrigues, I. A.,
Soares, R. M. A., Souto-Padrón, T.,
Alviano, C. S., and Lopes, A. H.
(2003). Antileishmanial activity of
a linalool-rich essential oil from
Croton cajucara. Antimicrob. Agents
Chemother. 47, 1895–1901.
Santoro, G. F., Cardoso, M. G.,
Guimarães, L. G. L., Mendonça, L.
Z., and Soares, M. J. (2007). Try-
panosoma cruzi: activity of essen-
tial oils from Achillea millefolium L.,
Syzygium aromaticum L. and Oci-
mum basilicum L. on epimastigotes
and trypomastigotes. Exp. Parasitol.
116, 283–290.
Santos, D. O., Coutinho, C. E., Madeira,
M. F., Bottino, C. G., Vieira, R.
T., Nascimento, S. B., Bernardino,
A., Bourguignon, S. C., Corte-Real,
S., Pinho, R. T., Rodrigues, C. R.,
and Castro, H. C. (2008). Leish-
maniasis treatment–a challenge that
remains: a review. Parasitol. Res. 103,
1–10.
Sarkar, A., Sen, R., Saha, P., Gan-
guly, S., Mandal, G., and Chatter-
jee, M. (2008). An ethanolic extract
of leaves of Piper betle (Paan) Linn
mediates its antileishmanial activ-
ity via apoptosis. Parasitol. Res. 102,
1249–1255.
Stuart, K., Brun, R., Croft, S., Fair-
lamb, A., Gürtler, R. E., McKer-
row, J., Reed, S., and Tarleton, R.
(2008). Kinetoplastids: related pro-
tozoan pathogens, different diseases.
J. Clin. Invest. 118, 1301–1310.
Sülsen, V., Frank, F. M., Carzola, S. I.,
Barrera, P., Freixa, B., Vila, R., Sosa,
M. A., Malchiodi, E. L., Muschi-
etti, L. V., and Martino, V. S.
(2011). Psilostachyin C: a natural
compound with trypanocidal activ-
ity. Int. J. Antimicrob. Agents 37,
536–543.
Tiuman, T. S., Santos, A. O., Ueda-
Nakamura, T., Dias Filho, B. P.,
and Nakamura, C. V. (2011). Recent
advances in leishmaniasis treatment.
Int. J. Infect. Dis. 15, 525–532.
Torres-Santos, E. C., Moreira, D. L.,
Kaplan, M. A., Meirelles, M. N.,
and Rossi-Bergmann, B. (1999).
Selective effect of 2’,6’-dihydroxy-
4’methoxychalcone isolated from
Piper aduncum on Leishmania
amazonensis. Antimicrob. Agents
Chemother. 43, 1234–1241.
Ueda-Nakamura, T., Mendonça-Filho,
R. R., Morgado-Díaz, J. A., Kore-
hisa Maza, P., Prado Dias Filho, B.,
Aparício Garcia Cortez, D., Alviano,
D. S., Rosa, M. S., Lopes, A. H.,
Alviano, C. S., and Nakamura, C.
V. (2006). Antileishmanial activity
of Eugenol-rich essential oil from
Ocimum gratissimum. Parasitol. Int.
55, 99–105.
Vendrametto, M. C., Santos, A. O.,
Nakamura, C. V., Dias Filho, B. P.,
Cortez, D. A., and Ueda-Nakamura,
T. (2010). Evaluation of antileish-
manial activity of eupomatenoid-5,
a compound isolated from leaves of
Piper regnellii var. pallescens. Para-
sitol. Int. 59, 154–158.
Wilkinson, S. R., and Kelly, J. M.
(2009). Trypanocidal drugs: mech-
anisms, resistance and new targets.
Expert Rev. Mol. Med. 11, 1–24.
Yardely, V., and Croft, S. (1999). In vitro
and in vivo activity of amphotericin
B-lipids formulations against exper-
imental Trypanosome cruzi infec-
tions. Am. J. Trop. Med. Hyg. 61,
193–197.
Zimmermman, S., Kaiser, M., Brun,
R., Hamburger, M., and Adams, M.
(2012). Cynaropicrin: the first plant
natural product with in vivo activity
against Trypanosoma brucei. Planta
Med. 78, 553–556.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 15 January 2012; accepted: 18
July 2012; published online: 06 August
2012.
Citation: Alviano DS, Barreto ALS,
Dias FdA, Rodrigues IdA, Rosa MdSdS,
Alviano CS and Soares RMdA (2012)
Conventional therapy and promising
plant-derived compounds against try-
panosomatid parasites. Front. Microbio.
3:283. doi: 10.3389/fmicb.2012.00283
This article was submitted to Fron-
tiers in Antimicrobials, Resistance and
Chemotherapy, a specialty of Frontiers in
Microbiology.
Copyright©2012Alviano,Barreto,Dias,
Rodrigues, Rosa, Alviano and Soares.
This is an open-access article distributed
under the terms of the Creative Com-
mons Attribution License, which per-
mits use, distribution and reproduction
in other forums, provided the original
authors and source are credited and sub-
ject to any copyright notices concerning
any third-party graphics etc.
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy August 2012 | Volume 3 | Article 283 | 10
